Send your comments and tips to email@example.com
Beth Israel Deaconess Medical Ctr.
Boston Medical Center
Brigham and Women's Hospital
Cambridge Health Alliance
Caritas St. Elizabeth's Medical Ctr.
Children's Hospital Boston
Dana-Farber Cancer Institute
Joslin Diabetes Center
Mass. General Hospital
Mass. Health Law
New England Baptist Hospital
Short White Coat
Tufts-New England Medical Center
UMass Memorial Medical Center
University of Massachusetts
VA Medical Centers
A Healthy Blog
Running A Hospital
Nature Network Boston
SciBos - Corie Lok's blog
Nurse at small
Dr. Gwenn Is In
Healthy Children blog
Other Globe Blogs
Elizabeth Cooney is a health reporter for the Worcester Telegram & Gazette.
Boston Globe Health and Science staff:
Karen Weintraub, Deputy Health and Science Editor, and Gideon Gil, Health and Science Editor.
Short White Coat blogger Ishani Ganguli
Short White Coat blogger Jennifer Srygley
Thursday, April 26, 2007
Genetic understanding of diabetes deepens
By Alice Dembner, Globe Staff
Four separate scientific teams, including one led by Harvard researchers, are today reporting progress toward unraveling the genetic basis of the most common form of diabetes.
They have identified three new genetic risk factors and confirmed five others that were discovered over the last few years. An additional risk factor identified by one group has not yet been confirmed by others.
Together, the genetic defects account for about 5 percent of the risk of getting the illness, said David Altshuler, associate professor of genetics and medicine at Harvard Medical School and a leader of one of the four teams that included the Broad Institute of Harvard and MIT.
"The picture that is emerging is of multiple genes, each with a modest effect" on diabetes, he said.
Overall, genetics account for about half the risk of getting type 2 diabetes, according to Altshuler. Environment and such behaviors as obesity and lack of exercise account for the remaining risk.
More than 20 million Americans now have type 2 diabetes and scientists estimate that about 54 million more are at risk of getting the illness. The disease harms the body's ability to control blood sugar and can lead to heart disease, blindness and early death.
"The pharmaceutical industry is absolutely salivating at all of these studies because they represent the best validation of a new drug target," said Dr. Francis Collins, director of the National Human Genome Research Institute and a leader of another of the teams. But Collins cautioned that it could be a decade before patients see any new drugs from the research.
The results were published today in the online editions of the journals Science and Nature Genetics.
They are all based on a new research technique called genome-wide association studies, in which scientists compare genetic samples from thousands of individuals with a specific illness to those without it. Differences between the two are examined as possible genetic causes of the disease.